Several drugs and natural compounds are known to be highly neurotoxic, triggering epileptic convulsions or seizures, and causing headaches, agitations, as well as other neuronal symptoms. The neurotoxic effects of some of these compounds, including theophylline and ginkgotoxin, have been traced to their inhibitory activity against human pyridoxal kinase (hPL kinase), resulting in deficiency of the active cofactor form of vitamin B6, pyridoxal 5′-phosphate (PLP). Pyridoxal (PL), an inactive form of vitamin B6 is converted to PLP by PL kinase. PLP is the B6 vitamer required as a cofactor for over 160 enzymatic activities essential in primary and secondary metabolism. We have performed structural and kinetic studies on hPL kinase with several potential inhibitors, including ginkgotoxin and theophylline. The structural studies show ginkgotoxin and theophylline bound at the substrate site, and are involved in similar protein interactions as the natural substrate, PL. Interestingly, the phosphorylated product of ginkgotoxin is also observed bound at the active site. This work provides insights into the molecular basis of hPL kinase inhibition and may provide a working hypothesis to quickly screen or identify neurotoxic drugs as potential hPL kinase inhibitors. Such adverse effects may be prevented by administration of an appropriate form of vitamin B6, or provide clues of how to modify these drugs to help reduce their hPL kinase inhibitory effects.
References
[1]
Kastner U, Hallmen C, Wiese M, Leistner E, Drewke C (2007) The human pyridoxal kinase, a plausible target for ginkgotoxin from ginkgo biloba. FEBS J 274: 1036–1045.
[2]
Seto T, Inada H, Kobayashi N, Tada H, Furukawa K, et al. (2000) Depression of serum pyridoxal levels in theophylline-related seizures. No To Hattatsu 32: 295–300.
[3]
Kuwahara H, Noguchi Y, Inaba A, Mizusawa H (2008) Case of an 81-year-old woman with theophylline-associated seizures followed by partial seizures due to vitamin B6 deficiency. Rinsho Shinkeigaku 48: 125–129.
[4]
Bonner AB, Peterson SL, Weir MR (1999) Seizures induced by theophylline and isoniazid in mice. Vet Hum Toxicol 41: 175–177.
[5]
Steichen O, Martinez-Almoyna L, De Broucker T (2006) Isoniazid induced neuropathy: Consider prevention. Rev Mal Respir 23: 157–160.
[6]
Spinneker A, Sola R, Lemmen V, Castillo MJ, Pietrzik K, et al. (2007) Vitamin B6 status, deficiency and its consequences-an overview. Nutr Hosp 22: 7–24.
Eliot AC, Kirsch JF (2004) Pyridoxal phosphate enzymes: Mechanistic, structural, and evolutionary considerations. Annu Rev Biochem 73: 383–415.
[9]
Nitsch C, Okada Y (1976) Differential decrease of GABA in the substantia nigra and other discrete regions of the rabbit brain during the preictal period of methoxypyridoxine-induced seizures. Brain Res 105: 173–178.
[10]
Laine-Cessac P, Cailleux A, Allain P (1997) Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs. Biochem Pharmacol 54: 863.
Delport R, Ubbink JB, Bosman H, Bissbort S, Vermaak WJ (1990) Altered vitamin B6 homeostasis during aminophylline infusion in the beagle dog. Int J Vitam Nutr Res 60: 35–40.
[13]
Ubbink JB, Bissbort S, Vermaak WJ, Delport R (1990) Inhibition of pyridoxal kinase by methylxanthines. Enzyme 43: 72–79.
[14]
Ubbink JB, Vermaak WJ, Delport R, Serfontein WJ, Bartel P (1990) The relationship between vitamin B6 metabolism, asthma, and theophylline therapy. Ann NY Acad Sci 585: 285–294.
[15]
Ubbink JB, Delport R, Becker PJ, Bissbort S (1989) Evidence of a theophylline-induced vitamin B6 deficiency caused by noncompetitive inhibition of pyridoxal kinase. J Lab Clin Med 113: 15–22.
[16]
Delport R, Ubbink JB, Serfontein WJ, Becker PJ, Walters L (1988) Vitamin B6 nutritional status in asthma: The effect of theophylline therapy on plasma pyridoxal-5′-phosphate and pyridoxal levels. Int J Vitam Nutr Res 58: 67–72.
[17]
Bartel PR, Ubbink JB, Delport R, Lotz BP, Becker PJ (1994) Vitamin B-6 supplementation and theophylline-related effects in humans. Am J Clin Nutr 60: 93–99.
[18]
Weir MR, Keniston RC, Enriquez JI, McNamee GA (1990) Depression of vitamin B6 levels due to theophylline. Ann Allergy 65: 59–62.
[19]
Weir MR, Keniston RC, Enriquez JI, McNamee GA (1991) Depression of vitamin B6 levels due to dopamine. Vet Hum Toxicol 33: 118–121.
[20]
Glenn GM, Krober MS, Kelly P, McCarty J, Weir M (1995) Pyridoxine as therapy in theophylline-induced seizures. Vet Hum Toxicol 37: 342–345.
Leistner E, Drewke C (2010) Ginkgo biloba and ginkgotoxin. J Nat Prod 73, 86–92.
[23]
Ubbink JB, Delport R, Bissbort S, Vermaak WJ, Becker PJ (1990) Relationship between vitamin B-6 status and elevated pyridoxal kinase levels induced by theophylline therapy in humans. J Nutr 120: 1352–1359.
[24]
McCormick DB, Chen H (1999) Update on interconversions of vitamin B-6 with its coenzyme. J Nutr 129: 325–327.
[25]
Jang YM, Kim DW, Kang TC, Won MH, Baek NI, et al. (2003) Human pyridoxal phosphatase: molecular cloning, functional expression, and tissue distribution. J Biol Chem 278: 50040–50046.
[26]
Clayton PT (2006) B6-responsive disorders: A model of vitamin dependency. J Inherit Metab Dis 29: 317–326.
[27]
Safo MK, Musayev FN, di Salvo ML, Hunt S, Claude JB, et al. (2006) Crystal structure of pyridoxal kinase from the Escherichia coli pdxK gene: Implications for the classification of pyridoxal kinases. J Bacteriol 188: 4542–4552.
[28]
Li MH, Kwok F, Chang WR, Lau CK, Zhang JP, et al. (2002) Crystal structure of brain pyridoxal kinase, a novel member of the ribokinase superfamily. J Biol Chem 277: 46385–46390.
[29]
Li MH, Kwok F, Chang WR, Liu SQ, Lo SC, et al. (2004) Conformational changes in the reaction of pyridoxal kinase. J Biol Chem 279: 17459–17465.
[30]
Cao P, Gong Y, Tang L, Leung YC, Jiang T (2006) Crystal structure of human pyridoxal kinase. J Struct Biol 154: 327–332.
[31]
Newman JA, Das SK, Sedelnikova SE, Rice DW (2006) The crystal structure of an ADP complex of bacillus subtilis pyridoxal kinase provides evidence for the parallel emergence of enzyme activity during evolution. J Mol Biol 363: 520–530.
[32]
Musayev FN, di Salvo ML, Ko TP, Gandhi AK, Goswami A, et al. (2007) Crystal structure of human pyridoxal kinase: Structural basis of M(+) and M(2+) activation. Protein Sci 16: 2184–2194.
[33]
Apgar JL, Tarka SM (1998) Methylxanthine composition and consumption patterns of cocoa and chocolate products. In: Spiller GA, editor. 171 p. Caffeine, CRC Press.
[34]
Tarka SM Jr, Morrissey RB, Apgar JL, Hostetler KA, Shively CA (1991) Chronic toxicity/carcinogenicity studies of cocoa powder in rats. Food Chem Toxicol 29: 7–19.
[35]
Tarka SM Jr (1982) The toxicology of cocoa and methylxanthines: A review of the literature. Crit Rev Toxicol 9: 275–312.
[36]
Brusick D, Myhr B, Galloway S, Rundell J, Jagannath DR, et al. (1986) Genotoxicity of theobromine in a series of short-term assays. Mutat Res 169: 105–114.
[37]
Brusick D, Myhr B, Galloway S, Rundell J, Jagannath DR, et al. (1986) Genotoxicity of cocoa in a series of short-term assays. Mutat Res 169: 115–121.
[38]
Wada K, Ishigaki S, Ueda K, Sakata M, Haga M (1985) An antivitamin B6, 4′-methoxypyridoxine, from the seed of ginkgo biloba. L Chem Pharm Bull (Tokyo). 33: 3555–3557.
[39]
Fiehe K, Arenz A, Drewke C, Hemscheidt T, Williamson RT, et al. (2000) Biosynthesis of 4′-O-methylpyridoxine (ginkgotoxin) from primary precursors. J Nat Prod 63, 185–189.
[40]
Kajiyama Y, Fujii K, Takeuchi H, Manabe Y (2002) Ginkgo seed poisoning. Pediatrics 109: 325–327.
[41]
Tutor-Crespo MJ, Hermida J, Tutor JC (2004) Activation of serum aminotransferases by pyridoxal-5′ -phosphate in epileptic patients treated with anticonvulsant drugs. Clin Biochem 37: 714–717.
[42]
Gandhi AK, Ghatge MS, Musayev FN, Sease A, Aboagye SO, et al. (2009) Kinetic and structural studies of the role of the active site residue Asp235 of human pyridoxal kinase. Biochem Biophys Res Commun 381: 12–15.
[43]
Safo MK, Musayev FN, Hunt S, di Salvo ML, Scarsdale N, et al. (2004) Crystal structure of the PdxY protein from Escherichia coli. J Bacteriol 186: 8074–8082.
[44]
Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, et al. (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280: 31208–31219.
[45]
Tang L, Li MH, Cao P, Wang F, Chang WR, et al. (2005) Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 280: 31220–31229.
[46]
Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D67: 235–242.
[47]
Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D54: 905–921.
[48]
Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D66: 486–501.
